膵管腺がん：市場分析、疫学、市場予測 (2034年)

当レポートでは、世界の主要7ヶ国 - 米国、欧州主要5ヶ国 (EU5：フランス・ドイツ・イタリア・スペイン・英国)、日本 - における膵管腺がんの疫学的動向と今後の市場見通しについて分析し、疾患の概要や市場の基本構造、現在の治療法とアンメットニーズ、有病者数の動向見通し、上市済み/治験中の治療薬のプロファイル、世界全体/各国の市場規模 (2020年～2034年)、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

調査概要

• 世界の膵管腺がん市場は今後数年間で、この疾患に対する認知度の高まりと、世界の医療費の増加傾向により、変化するとみられます。
• 企業や研究機関は、膵管腺がんの研究開発に影響を与える可能性のある課題を評価し、機会を求めています。開発中の治療法は、病態を治療/改善するための新規アプローチに焦点を当てています。
• 主要企業は膵管腺がんの治療法開発に関与しています。新たな治療法の登場は膵管腺がん市場に大きな影響を与えるでしょう。
• 疾患病態の理解が深まれば、膵管腺がんの新規治療薬の開発にも貢献する、と考えられています。
• 異なる開発段階 (第III相および第II相) におけるパイプライン資産の詳細な分析や、各々のパイプライン製品の新たな動向とその比較分析 (詳細な臨床プロファイルを含む)、主要なクロス競合、製品の発売日・開発活動といった情報が、研究開発活動の全体的なシナリオを識別することにより、治療ポートフォリオに関する意思決定プロセスで、クライアントをサポートします。

目次

第1章 主な考察

第2章 膵管腺がん：エグゼクティブサマリー

第3章 膵管腺がん：競合情報分析

第4章 膵管腺がん：市場概要

• 膵管腺がんの全体的な市場シェア (2020年)
• 膵管腺がんの全体的な市場シェア (2034年)

第5章 膵管腺がん：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理
• 危険因子
• 診断方法

第6章 ペイシェント・ジャーニー

第7章 膵管腺がんの疫学と患者人口

• 疫学的動向：主な調査結果
• 仮定と理論的根拠：主要7ヶ国
• 疫学シナリオ：主要7ヶ国
  • 膵管腺がん：主要7ヶ国における疫学シナリオ (2020年～2034年)
• 米国の疫学
  • 米国国内の膵管腺がんの疫学シナリオ (2020年～2034年)
• 欧州主要5ヶ国 (5EU) の疫学：国別
  • ドイツの疫学
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学
  • 日本の疫学

第8章 治療アルゴリズム、現在の治療、医療行為

• 膵管腺がんの治療・管理方法
• 膵管腺がんの治療アルゴリズム

第9章 アンメットニーズ

第10章 膵管腺がん治療薬の主要評価項目

第11章 上市済み製品

• 主要7ヶ国の上市済み製品の一覧
• 薬剤の名称：企業名
  • 製品概要
  • 規制のマイルストーン
  • その他の開発活動
  • 重要な治験
  • 重要な治験：概要

第12章 新たな治療薬

• キークロス
• 薬剤の名称：企業名
  • 製品概要
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
  • 製品プロファイル

第13章 膵管腺がん：主要7ヶ国の市場分析

• 主な調査結果
• 膵管腺がんの市場規模：主要7ヶ国
• 膵管腺がんの市場規模：主要7ヶ国、治療薬別

第14章 属性分析

第15章 主要7ヶ国：市場の将来展望

• 米国の市場規模
  • 膵管腺がんの全体的な市場規模
  • 市場規模：治療薬別
• 欧州主要5ヶ国 (EU5) 市場：市場規模と将来展望
• ドイツの市場規模
  • 膵管腺がんの全体的な市場規模
  • 市場規模：治療薬別
• フランスの市場規模
• イタリアの市場規模
• スペインの市場規模
• 英国の市場規模
  • 膵管腺がんの全体的な市場規模
  • 市場規模：治療薬別
• 日本市場：将来展望
  • 日本の市場規模

第16章 膵管腺がんのアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場抑制要因

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Pancreatic Ductal Adenocarcinoma Epidemiology (2020-2034)
• Table 2: 7MM Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases (2020-2034)
• Table 3: Pancreatic Ductal Adenocarcinoma Epidemiology in the United States (2020-2034)
• Table 4: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Pancreatic Ductal Adenocarcinoma Epidemiology in Germany (2020-2034)
• Table 6: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Pancreatic Ductal Adenocarcinoma Epidemiology in France (2020-2034)
• Table 8: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Pancreatic Ductal Adenocarcinoma Epidemiology in Italy (2020-2034)
• Table 10: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Pancreatic Ductal Adenocarcinoma Epidemiology in Spain (2020-2034)
• Table 12: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Pancreatic Ductal Adenocarcinoma Epidemiology in the UK (2020-2034)
• Table 14: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Pancreatic Ductal Adenocarcinoma Epidemiology in Japan (2020-2034)
• Table 16: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Pancreatic Ductal Adenocarcinoma Epidemiology (2020-2034)
• Figure 2: 7MM Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Pancreatic Ductal Adenocarcinoma Epidemiology in the United States (2020-2034)
• Figure 4: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Pancreatic Ductal Adenocarcinoma Epidemiology in Germany (2020-2034)
• Figure 6: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Pancreatic Ductal Adenocarcinoma Epidemiology in France (2020-2034)
• Figure 8: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Pancreatic Ductal Adenocarcinoma Epidemiology in Italy (2020-2034)
• Figure 10: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Pancreatic Ductal Adenocarcinoma Epidemiology in Spain (2020-2034)
• Figure 12: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Pancreatic Ductal Adenocarcinoma Epidemiology in the UK (2020-2034)
• Figure 14: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Pancreatic Ductal Adenocarcinoma Epidemiology in Japan (2020-2034)
• Figure 16: Pancreatic Ductal Adenocarcinoma Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Pancreatic Ductal Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Pancreatic Ductal Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Ductal Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pancreatic Ductal Adenocarcinoma market report provides current treatment practices, emerging drugs, Pancreatic Ductal Adenocarcinoma market share of the individual therapies, current and forecasted Pancreatic Ductal Adenocarcinoma market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Pancreatic Ductal Adenocarcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Pancreatic Ductal Adenocarcinoma Disease Understanding and Treatment Algorithm

The DelveInsight Pancreatic Ductal Adenocarcinoma market report gives a thorough understanding of the Pancreatic Ductal Adenocarcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Pancreatic Ductal Adenocarcinoma.

Treatment

It covers the details of conventional and current medical therapies available in the Pancreatic Ductal Adenocarcinoma market for the treatment of the condition. It also provides Pancreatic Ductal Adenocarcinoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Pancreatic Ductal Adenocarcinoma Epidemiology

The Pancreatic Ductal Adenocarcinoma epidemiology division provide insights about historical and current Pancreatic Ductal Adenocarcinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pancreatic Ductal Adenocarcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Pancreatic Ductal Adenocarcinoma Epidemiology

The epidemiology segment also provides the Pancreatic Ductal Adenocarcinoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pancreatic Ductal Adenocarcinoma Drug Chapters

Drug chapter segment of the Pancreatic Ductal Adenocarcinoma report encloses the detailed analysis of Pancreatic Ductal Adenocarcinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Pancreatic Ductal Adenocarcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Pancreatic Ductal Adenocarcinoma treatment.

Pancreatic Ductal Adenocarcinoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Pancreatic Ductal Adenocarcinoma treatment.

Pancreatic Ductal Adenocarcinoma Market Outlook

The Pancreatic Ductal Adenocarcinoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Pancreatic Ductal Adenocarcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Pancreatic Ductal Adenocarcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Pancreatic Ductal Adenocarcinoma market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Pancreatic Ductal Adenocarcinoma market in 7MM.

The United States Market Outlook

This section provides the total Pancreatic Ductal Adenocarcinoma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Pancreatic Ductal Adenocarcinoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Pancreatic Ductal Adenocarcinoma market size and market size by therapies in Japan is also mentioned.

Pancreatic Ductal Adenocarcinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Pancreatic Ductal Adenocarcinoma market or expected to get launched in the market during the study period 2020-2034. The analysis covers Pancreatic Ductal Adenocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pancreatic Ductal Adenocarcinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Pancreatic Ductal Adenocarcinoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Pancreatic Ductal Adenocarcinoma emerging therapies.

Reimbursement Scenario in Pancreatic Ductal Adenocarcinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Pancreatic Ductal Adenocarcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pancreatic Ductal Adenocarcinoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Pancreatic Ductal Adenocarcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Pancreatic Ductal Adenocarcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Pancreatic Ductal Adenocarcinoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Pancreatic Ductal Adenocarcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Pancreatic Ductal Adenocarcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pancreatic Ductal Adenocarcinoma market

Report Highlights:

• In the coming years, Pancreatic Ductal Adenocarcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Ductal Adenocarcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Pancreatic Ductal Adenocarcinoma. Launch of emerging therapies will significantly impact the Pancreatic Ductal Adenocarcinoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pancreatic Ductal Adenocarcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Pancreatic Ductal Adenocarcinoma Report Insights

• Patient Population
• Therapeutic Approaches
• Pancreatic Ductal Adenocarcinoma Pipeline Analysis
• Pancreatic Ductal Adenocarcinoma Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Pancreatic Ductal Adenocarcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Pancreatic Ductal Adenocarcinoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Pancreatic Ductal Adenocarcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Pancreatic Ductal Adenocarcinoma market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Pancreatic Ductal Adenocarcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Pancreatic Ductal Adenocarcinoma market size during the forecast period (2024-2034)?
• At what CAGR, the Pancreatic Ductal Adenocarcinoma market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Pancreatic Ductal Adenocarcinoma market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Pancreatic Ductal Adenocarcinoma market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Pancreatic Ductal Adenocarcinoma?
• What is the historical Pancreatic Ductal Adenocarcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Pancreatic Ductal Adenocarcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Pancreatic Ductal Adenocarcinoma?
• Out of all 7MM countries, which country would have the highest prevalent population of Pancreatic Ductal Adenocarcinoma during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Pancreatic Ductal Adenocarcinoma treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Pancreatic Ductal Adenocarcinoma in the USA, Europe, and Japan?
• What are the Pancreatic Ductal Adenocarcinoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma?
• How many therapies are developed by each company for Pancreatic Ductal Adenocarcinoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Pancreatic Ductal Adenocarcinoma treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Ductal Adenocarcinoma therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic Ductal Adenocarcinoma and their status?
• What are the key designations that have been granted for the emerging therapies for Pancreatic Ductal Adenocarcinoma?
• What are the global historical and forecasted market of Pancreatic Ductal Adenocarcinoma?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Pancreatic Ductal Adenocarcinoma market
• To understand the future market competition in the Pancreatic Ductal Adenocarcinoma market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Pancreatic Ductal Adenocarcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Pancreatic Ductal Adenocarcinoma market
• To understand the future market competition in the Pancreatic Ductal Adenocarcinoma market

Table of Contents

1. Key Insights

2. Executive Summary of Pancreatic Ductal Adenocarcinoma

3. Competitive Intelligence Analysis for Pancreatic Ductal Adenocarcinoma

4. Pancreatic Ductal Adenocarcinoma: Market Overview at a Glance

• 4.1. Pancreatic Ductal Adenocarcinoma Total Market Share (%) Distribution in 2020
• 4.2. Pancreatic Ductal Adenocarcinoma Total Market Share (%) Distribution in 2034

5. Pancreatic Ductal Adenocarcinoma: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Pancreatic Ductal Adenocarcinoma Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Pancreatic Ductal Adenocarcinoma Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Pancreatic Ductal Adenocarcinoma Treatment and Management
• 8.2. Pancreatic Ductal Adenocarcinoma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Pancreatic Ductal Adenocarcinoma Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Pancreatic Ductal Adenocarcinoma: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Pancreatic Ductal Adenocarcinoma Market Size in 7MM
• 13.3. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Pancreatic Ductal Adenocarcinoma Total Market Size in the United States
  • 15.1.2. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Pancreatic Ductal Adenocarcinoma Total Market Size in Germany
  • 15.3.2. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Pancreatic Ductal Adenocarcinoma Total Market Size in France
  • 15.4.2. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Pancreatic Ductal Adenocarcinoma Total Market Size in Italy
  • 15.5.2. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Pancreatic Ductal Adenocarcinoma Total Market Size in Spain
  • 15.6.2. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Pancreatic Ductal Adenocarcinoma Total Market Size in the United Kingdom
  • 15.7.2. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Pancreatic Ductal Adenocarcinoma Total Market Size in Japan
  • 15.8.3. Pancreatic Ductal Adenocarcinoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Pancreatic Ductal Adenocarcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.